SAB Biotherapeutics (SABS) Added to NASDAQ Biotechnology Index
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
SAB Biotherapeutics (SABS) Climbs 27% After Reporting SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
December 16, 2021 6:13 AM ESTSAB Biotherapeutics (NASDAQ: SABS) Climbs 27% After Reporting SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
... MoreSAB Biotherapeutics (SABS) Reports SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
December 16, 2021 6:01 AM ESTSAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced data demonstrating that SAB-185, the companys therapeutic candidate for the treatment of COVID-19 infections, retains neutralization activity against the Omicron SARS-CoV-2 variant in an in vitro pseudovirus model. The data were generated by scientists at the US Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER).
These in vitro data demonstrate that SAB-185 retains neutralization activity against the... More
